Referenze

1. AIOM, AIRTUM. I numeri del cancro in Italia
2016. Il Pensiero Scientifico Editore. 2016
2. De Marzo AM, Nelson WG, Isaacs WB, Epstein JI.
Pathological and molecular aspects of
Prostate Cancer. Lancet. 361: 955-964, 2003.
3. Chan JM, Gann PH, Giovannucci EL. Role of diet in prostate cancer development and progression. J Clin Oncol. 10: 8152-60, 2005.
4. Woutersen RA, Appel MJ, Van Garderen-Hoetmer A, Wijnands MV. Dietary fat and carcinogenesisi. Mutat Res. 443: 111-27,
1999.
5. Shirai T, Asamoto M, Takahashi S, et al. Diet and prostate cancer. Toxicology. 181-182: 89-
94, 2002.
6. Yang CS, Lambert JD, Hou Z, et al. Molecular targets for the cancer preventive activity of tea polyphenols. Mol Carcinog. 45: 431-5,
2006.
7. Syed DN, Khan N, Afaq F, Mukhatar H.
Chemoprevention of prostate cancer through dietary agents: progress and promise. Cancer Epidemiol Biomarkers Prev.
16: 2193-203, 2007.
8. Hsing AW. Hormones and prostate cancer:
what’s the next? Epidemiol Rev, 23: 42-58,
2001.
9. Seeram NP, Aronson WJ, Zhang Y et al.
Pomegranate Ellagitannin – derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem. 55: 7732-7, 2007.
10. Cook LS, Goldoft M, Schwartz SM, et al.
Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol. 161:
152-155, 1999.
11. Bozeman CB, Carver BS, Caldito G, Venable DD, Easthman JA. Prostate cancer in patients with an abnormal digital rectal examination and serum prostate specific antigen less than 4.0 ng/mL. Urology. 66: 803-7, 2005.
12. Vasilareas D, Mitterdorfer AJ, Maher PO, Lalak A.
Prostate cancer detection with digital rectal examination, prostate-specific antigen, transrectal ultrasonography and biopsy in clinical urological practice. BJU Int. 95: 545-
8, 2005.
13. Devonec M, Fendler JP, Monsailler M, et al. The significance of the prostatic hypoechoic area : results in 226 ultrasonically guided prostatic biopsies. J Urol. 143: 316, 1990.
14. Esposti PL, Elman A, Norlen H. Complications of transrectal aspiration biopsy of the
prostate. Scand J Urol Nephrol. 9: 208-13,
1975.
15. Djavan B, Zlotta AR, Byttebier G, Shariat S, Omar M, Schulman CC, Marberger M. Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol. 160: 411-8, 1998.
16. Eastham JA, Kattan MW, Riedel E, Begg CB, Wheeler TM, Gerigk C, Gonen M, Reuter V, Scardino PT. Variation of serum prostate- specific antigen levels: an evalutation of year-to-year fluctuations. JAMA. 289: 2695-
700, 2003.
17. Hoffman RM, Clanon DL, Littenberg B, Frank JJ, Peirce JC. Using the free-to-total prostate- specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels. J Gen Intern Med. 15: 739-48, 2000.
18. Brawer MK, Cheli CD, Neaman IE, Goldblatt J, Smith C, Schwartz MK, Bruzek DJ, Morris DL, Sokoll LJ, Chan DW, Yeung KK, Partin AW, Allard WJ. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol. 163: 1476-80, 2000.
19. Beneduce L, Prayer-Galletti T, Marcello Grimani Giustinian A, Gallotta A, Fracalanza S, Betto G, Artibani W, Pagano F and Fassina G. The occurrence of Prostate Specific Antigen- IgM immune complexes (IC) as novel serum biomarker for prostate cancer. Euro Urol Supp. 5(2): 163, 2006.
20. Beneduce L, Prayer-Galletti T, Marcello Grimani Giustinian A, Gallotta A, Betto G, Pagano F, Fassina G. Detection of prostate specific antigen coupled to immunoglobulin M In prostate cancer patients. Cancer Detect Prev.
31: 402-7, 2007.
21. Prayer-Galetti T, Beneduce L, Dal Moro F, Betto G, Fassina G, Pagano F. PSA-IgM complessato (IC) un nuovo biomarcatore per il carcinoma della prostata. SIU Annual Congress, Bologna, 17–21 June 2006.
22. Prayer-Galetti T, Beneduce L, Dal Moro F, Betto G, Fassina G, Pagano F. Influenza dell’Età dei Pazienti, dei Valori di PSA Sierico e del Grado di Differenziazione Tumorale sui Livelli Circolanti degli Immuno-Complessi PSA-IgM. SIU Annual Congress, Bari, 27
September – 1 October 2007.
23. Zani D, Pezzoni G, Pettenò A, Simeone C, Beneduce L, Gallotta A, Fassina G, Cosciani Cunico S. Validazione dell’uso di PSA e immunocomplessi PSA-IgM nella diagnostica della neoplasia prostatica organo confinata. SIU Annual Congress, Rome, 22-28 September 2008.
24. Zani D, Costa S, Gatti L, Presenti N, Pettino A, Zambolin T, Simeone C, Cosciali Cunico S, Leon A, Zuin J, Fassina G, Beneduce L. Studio dell’ associazione PSA-IgM e PSA totale per la diagnosi del carcinoma prostatico. SIU Annual Congress, Rimini, 4–7 October 2009.
25. Gallotta A, Giannarini G, Laurini L, Zani D, Garbeglio A, Guazzieri S, Plebani M, Fassina G, Zattoni F. Clinical validation of the iXip index in avoiding unnecessary prostate biopsy : results from a prospective multicenter study involving 426 patients. Cancer Treat Res Comm. 10: 40-45, 2017.
26. Gallotta A, Ziglioli F, Ferretti S, Maestroni U, Moretti M, Aloe R, Gnocchi C, Di Palo M, Fassina G. A novel algorithm for the prediction of prostate cancer in clinically suspected patients. Cancer Biomark. 13: 227-34, 2013.
27. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, van Gils MP, Schalken JA. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 54:
1081-8, 2008.
28. Tinzl M, Marberger M, Horvath S, Chypre C.
DD3PCA3 RNA analysis in urine—a new perspective for detecting prostate cancer. Eur Urol. 46: 182-6, 2004.
29. Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, Lonigro RJ, Tsodikov A, Wei JT, Tomlins SA, Chinnaiyan AM. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 68: 645-9, 2008.
30. Anelli MC. Un nuovo test per la determinazione di un precursore del PSA può migliorare la specificità del PSA totale: il dosaggio Access® Hybritech® p2PSA Ligand Assay. 15: 176-80, 2010.
31. Guazzoni G, Nava L, Lazzeri M, Scattoni V, Lughezzani G, Maccagnano C, Dorigatti F, Ceriotti F, Pontillo M, Bini V, Freschi M, Montorsi F, Rigatti P. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol. 60: 214-22, 2011.
32. Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, Partin AW, Srivastava S, Thompson IM, Wei JT, Zhang Z, Chan DW. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev. 19: 1193-200, 2010.